BioCryst Pharmaceuticals(BCRX)
DURHAM, NC
PharmaceuticalFocus: Small Molecules
BioCryst Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Funding Stage
PUBLIC
Open Jobs
17
Products & Portfolio (3)
ORLADEYO
berotralstat hydrochloride
Launch
ORAL · PELLETS
activity. Plasma kallikrein is a protease that cleaves high-molecular-weight kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Berotralstat decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE.
2025
0
ORLADEYO
berotralstat hydrochloride
Peak
ORAL · CAPSULE
activity. Plasma kallikrein is a protease that cleaves high-molecular-weight kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Berotralstat decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE.
2020
0
RAPIVAB
peramivir
LOE Approaching
SMINTRAVENOUS · SOLUTION
Neuraminidase Inhibitors
2014
15
Pipeline & Clinical Trials
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replaceme
InfluenzaClinical Trials (1)
NCT01146353Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
N/ABerotralstat
Hereditary AngioedemaClinical Trials (1)
NCT04428632Oral Berotralstat Expanded Access Program
N/ABCX7353 and probes
Hereditary AngioedemaClinical Trials (1)
NCT02819102An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
Phase 1forodesine hydrochloride
LymphomaClinical Trials (1)
NCT00098332Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
Phase 1BCX7353
Hereditary AngioedemaClinical Trials (1)
NCT03136237A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
Phase 1forodesine hydrochloride
CancerClinical Trials (1)
NCT00073944BCX-1777 in Treating Patients With Refractory Cancer
Phase 1BCX7353
Hereditary AngioedemaClinical Trials (1)
NCT03202784A Relative Bioavailability Study of Two Formulations of BCX7353
Phase 1galidesivir
Marburg Virus DiseaseClinical Trials (1)
NCT03800173A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
Phase 1BCX7353
Hereditary AngioedemaClinical Trials (1)
NCT02448264First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
Phase 1Phase 1
Clinical Trials (1)
NCT06100900Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1avoralstat
Diabetic Macular Edema (DME)Clinical Trials (1)
NCT07228559A Study of Avoralstat In Participants With Diabetic Macular Edema
Phase 1BCX4161
Hereditary AngioedemaClinical Trials (1)
NCT02218294Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
Phase 1BCX4161
Hereditary AngioedemaClinical Trials (1)
NCT02125162A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
Phase 1Galidesivir
COVID-19Clinical Trials (1)
NCT03891420A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
Phase 1Peldesine
HIV InfectionsClinical Trials (1)
NCT00002237A Study of Peldesine (BCX-34) in HIV-Infected Patients
Phase 1BCX17725
Netherton SyndromeClinical Trials (1)
NCT06539507A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Phase 1BCX4430
Filovirus InfectionsClinical Trials (1)
NCT02319772A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Phase 1forodesine hydrochloride
LymphomaClinical Trials (1)
NCT00061880BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
Phase 1/2BCX-1777
Leukemia, LymphocyticClinical Trials (1)
NCT00035022Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT04330534First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
Phase 1/2forodesine hydrochloride
B-cell Acute Lymphoblastic LeukemiaClinical Trials (1)
NCT00289562Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
Phase 1/2placebo
GoutClinical Trials (1)
NCT00985127Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
Phase 2Peramivir 200 mg
InfluenzaClinical Trials (1)
NCT00453999Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
Phase 2Phase 2
Clinical Trials (1)
NCT05116787BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
Phase 2Phase 2
Clinical Trials (1)
NCT05116774BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
Phase 2forodesine HCl
Chronic Lymphocytic Leukemia (CLL)Clinical Trials (1)
NCT00640523Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Phase 2Phase 2
Clinical Trials (1)
NCT05741346Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
Phase 2Placebo
GoutClinical Trials (1)
NCT01407874A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
Phase 2BCX7353
Hereditary Angioedema (HAE)Clinical Trials (1)
NCT03240133Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
Phase 2Peramivir 150 mg
InfluenzaClinical Trials (1)
NCT00419263Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
Phase 2ulodesine
GoutClinical Trials (1)
NCT01265264Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
Phase 2Peramivir
Acute, Uncomplicated Human InfluenzaClinical Trials (1)
NCT00705406A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
Phase 2BCX4161
Hereditary AngioedemaClinical Trials (1)
NCT01984788Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
Phase 2BCX9930
Complement 3 GlomerulopathyClinical Trials (1)
NCT05162066Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Phase 2Forodesine Hydrochloride Sterile Solution, 5 mg/mL
LeukemiaClinical Trials (1)
NCT00419081Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
Phase 2forodesine hydrochloride
Leukemia, Lymphocytic, ChronicClinical Trials (1)
NCT00289549Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2Forodesine 200 mg
Cutaneous T-cell Lymphoma (CTCL),Clinical Trials (1)
NCT00501735Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Phase 2Phase 2
Clinical Trials (1)
NCT04702568A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2forodesine hydrochloride
Leukemia, T-CellClinical Trials (1)
NCT00095381Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
Phase 2Placebo
GoutClinical Trials (1)
NCT01129648Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
Phase 2BCX7353
Hereditary Angioedema (HAE)Clinical Trials (1)
NCT02870972Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
Phase 2BCX7353
Hereditary AngioedemaClinical Trials (1)
NCT03472040A Long Term Safety Study of BCX7353 in Hereditary Angioedema
Phase 2/3BCX4161
Hereditary AngioedemaClinical Trials (1)
NCT0230362612-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Phase 2/3Peramivir
InfluenzaClinical Trials (1)
NCT02665351Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
Phase 2/3Berotralstat
Hereditary AngioedemaClinical Trials (1)
NCT05453968Berotralstat Treatment in Children With Hereditary Angioedema
Phase 3Peramivir
InfluenzaClinical Trials (1)
NCT01224795A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
Phase 3Peramivir
InfluenzaClinical Trials (1)
NCT00610935Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
Phase 3Peramivir
InfluenzaClinical Trials (1)
NCT02635724Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Phase 3BCX7353 capsules
Hereditary AngioedemaClinical Trials (1)
NCT03485911Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Phase 3Peramivir 150mg
InfluenzaClinical Trials (1)
NCT00486980Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
Phase 3Open Jobs (17)
Exec. Director, Global Patient Engagement
US_North Carolina_Headquarters
Research & DevelopmentYesterday
Sr. Manager, Regulatory Affairs
US_North Carolina_Remote
Regulatory Affairs4d ago
Director, Global Regulatory CMC
US_North Carolina_Remote
Regulatory Affairs1w ago
Director, Toxicology
US_North Carolina_Remote
Research & Development1w ago
Sr. Advanced Analytics Manager
US_North Carolina_Remote
Research & Development1w ago
Assoc. Director, Global Data Science Operations
US_North Carolina_Remote
Data Science & AI2w ago
Director, Product Communications
US_North Carolina_Remote
Research & Development2w ago
VP, Commercial Manufacturing & Supply
US_North Carolina_Remote
3w ago
Medical Director - GDSP (Contract)
US_North Carolina_Remote
3w ago
Sr. Manager, Quality Systems & Continuous Improvement
US_North Carolina_Remote
3w ago
Sr. Business Systems Manager
US_North Carolina_Remote
3w ago
Assoc. Director, IT Business Partner - G&A
US_North Carolina_Remote
3w ago
Sr. Corporate & Securities Counsel
US_North Carolina_Remote
3w ago
Sr. QA Specialist
US_North Carolina_Remote
1mo ago
Medical Science Liaison - Southeast region
US_North Carolina_Remote
1mo ago
HR Operations & Payroll Analyst
US_North Carolina_Remote
1mo ago
Intern, Translational Modeling
US_North Carolina_Headquarters
1mo ago
Interview Prep Quick Facts
Founded: 1986
Portfolio: 3 approved products, 56 clinical trials
Top TAs: Infectious Diseases, Oncology, Metabolic Diseases
SEC Filings: 2 available
Open Roles: 17 active jobs
Portfolio Health
Launch1 (33%)
Peak1 (33%)
LOE Approaching1 (33%)
3 total products
Therapeutic Area Focus
Infectious Diseases
1 marketed12 pipeline
Oncology
10 pipeline
Metabolic Diseases
4 pipeline
Nephrology
2 pipeline
Respiratory
2 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$331M22%
R&D Spend
$217M(65%)15%
Net Income
-$227MCash
$111MHiring Trend
Stable
17
Open Roles
+4
Added
-5
Filled/Removed
Based on last 4 crawl cycles